In brief Progress
The first dystrophin gene therapy phase I clinical trial for Duchenne/Becker muscular dystrophy is completed. Optimized vector cassette design leads to enhanced transgene expression. Optimized protocols for local administration of plasmid DNA vectors have achieved therapeutic levels of expression in a single muscle. Multiple muscle groups can be transfected efficiently with plasmid DNA by optimized intravenous and intra-arterial approaches. Novel adeno-associated virus (AAV) serotypes lead to very efficient systemic transduction of skeletal muscle with truncated microdystrophin cDNAs. Expanding the packing capacity of AAV allows delivery of larger dystrophin molecules to dystrophic muscle. Improved chemistries of antisense oligonucleotides improve efficiency of exon skipping. Alternative chemistries allow efficient systemic delivery of antisense oligonucleotides. Two phase I clinical trials for exon skipping in Duchenne muscular dystrophy (DMD) are in progress. Development of adjuvant therapies to augment muscle growth.
Prospects
Regional delivery protocols for plasmid DNA will improve further, with clinical trial planned. Enhanced muscle tropism of AAV vectors will lead to lower viral load required for therapeutic levels of dystrophin expression. Trans-splicing/overlapping AAV vectors for the delivery of full-length dystrophin will be developed. Success of initial clinical trial to be repeated: AAV and antisense -exon skipping trials are ongoing. Adjuvant therapies to increase muscle mass to be used in conjunction with dystrophin therapies. Effective gene therapy for DMD is on the horizon. This trial entailed a conservatively designed programme studying the intramuscular (i.m.) injection of low amounts of plasmid DNA expressing full-length human dystrophin under the control of the cytomegalovirus (CMV) promoter. The study aimed to demonstrate transgene expression at the injected site and to provide evidence of safety of such an approach. I.m. plasmid injection of the radial muscle was performed in nine Duchenne muscular dystrophy (DMD) or Becker Muscular dystrophy (BMD) patients. Patients were injected either once with 200 or 600 mg of plasmid, or twice with 600 mg 2 weeks apart. Plasmid was detected in all patients, demonstrating successful gene transfer. However, only low dystrophin protein expression was detected in six of nine patients; this was confirmed by detection of exogenous dystrophin mRNA. These findings may reflect the low doses of plasmid used. Importantly, the study showed no adverse clinical or immunological reactions either to the injected DNA or to dystrophin. This is a landmark study showing that in principle plasmid DNA can result in dystrophin expression, although there is a need for a vast improvement in the efficiency of gene transfer and the ability to deliver plasmid DNA to multiple muscles if this is to be a valid approach for the treatment of muscular dystrophies.
Optimized vector cassette design leads to enhanced transgene expression
Many vector design features have been previously reviewed and only a selection of strategies will be discussed here. Briefly, promoter choice is critical, and muscle-specific promoters, both natural and synthetic have been developed for high expression in skeletal and cardiac muscle. 2 Additional elements including enhancers and nuclear transport enhancers which promote transport of the plasmid from the cytoplasm to the nucleus, such as the simian virus 40 enhancer have been included in expression cassettes to further increase the efficiency of expression (up to 20-fold) (reviewed by Lu et al.
2 ). Other advances have centred on enhancing transgene expression at the post-transcriptional and translational levels. An element, which has been shown to enhance levels of transgene expression, from both plasmid and viral vectors, is the woodchuck post-transcriptional response element (WPRE). WPRE is a 600 bp non-coding cis-acting element, which increases stability and transport of mRNA from the nucleus to the cytoplasm, such that higher levels of transcript are available for translation. Inclusion of WPRE elements into plasmid DNA vectors has proven to be beneficial in genetic vaccination strategies. Garg et al.
3 demonstrated significantly higher levels of b-galactosidase and haemaglutinin expression in muscle after the inclusion of a WPRE element, and improved levels of viral transgene expression and virus production. 4 There have been concerns between WPRE and hepatocarcinomas; the WPRE contains an enhancing element, We1 that acts as a promoter for the woodchuck hepatitis virus X protein and also contains the first 60 amino acids of the X protein. A homologous X protein is found in mammalian hepatitis B virus and when mutated, can lead to hepatocellular carcinomas. Mutations leading to neoplastic transformations arise from c-terminal deletions of protein X, and hence the concerns. 5 However, although having the potential to be oncogenic, the WPREs in preclinical vectors do not have the second protein X enhancer, We2/En2, suggestive that the X promoter is inactive in this context. 6 However, to avoid any potential complications, WPRE elements have been generated ablating the We1 and protein X translational initiation site, which have been shown to still enhance gene expression. 7 Sequences flanking the AUG start codon within an mRNA can influence its recognition by eukaryotic ribosomes. A consensus 'Kozak' sequence has been shown to be important and required for the optimal translation of mammalian genes (reviewed by Garmory et al. 8 ). A second point at which efficiency of translation has been improved is optimization of codon usage. Codon bias is observed in many species with the greatest deviation from random codon usage seen in highly expressed genes. Optimization of codon usage for the species in which the transgene is expressed has resulted in significantly higher levels of protein expression, particularly when expressing viral proteins for genetic vaccination purposes (reviewed by Garmory et al. 8 ). Thus, in our laboratory, inclusion of a consensus Kozak sequence and optimization of codon usage has led to significantly increased levels of microdystrophin expression following plasmid electrotransfer (Foster H et al., unpublished data).
Optimized protocols for local administration of plasmid DNA vectors have achieved therapeutic levels of expression in a single muscle
The major hurdle for the use of plasmid DNA for the treatment of DMD is the enormous amount of tissue (40% of body mass), which needs to be transfected at high efficiency. Significant progress has been made in improving levels of transfection efficiency following both i.m. injection and regional delivery of plasmids. A number of strategies have been employed to improve efficiencies following direct injection. Amphiphilic block co-polymers have improved the efficiency of plasmid injection into normal and dystrophic muscle, 9 as has the use of microbubble ultrasound. 10 However, although both these methods show a significant improvement over direct injection alone, efficiencies are not in the therapeutic range. However, importantly it has been demonstrated that microbubble ultrasound can be used to direct plasmid expression in the heart, 11 which is otherwise a difficult organ to target with plasmid vectors.
The most dramatic improvement in plasmid gene transfer following i.m. injection has been achieved with the use of electrotransfer. Electrotransfer involves the i.m. injection of plasmid DNA, immediately followed by a series of electrical pulses, the parameters and applications of which have been extensively reviewed by Bloquel et al., 12 and Andre and Mir. 13 As with other gene transfer technologies, it is important to determine optimal conditions to maximize efficiency and reduce damage. More recently, the application of hyaluronidase before electrotransfer significantly increased transfection efficiency and also led to a reduction in procedure- alternatively, electrotransfer parameters may need to be further optimized for large plasmids. An in vivo nuclear magnetic resonance imaging system has been developed to allow the efficiency and toxicity of electrotransfer to be assessed, which will hopefully lead to the further refinement of this methodology. 15 Interestingly, electrotransfer has recently been used to deliver an integrating dystrophin plasmid to dystrophic muscle. 16 Muscles were co-injected with a plasmid containing the phage integrase jC31 gene, with a plasmid encoding dystrophin and a att recognition sequence. jC31 integrase directs integration of the therapeutic plasmid at so-called 'pseudo attP' sites within the mammalian genome. This led to a twofold increase in the number of dystrophinpositive fibres with an eightfold increase in mRNA levels. Although this approach led to higher levels and greater distribution of dystrophin expression, little is known about the specificity of integration and, therefore, more safety work is needed before such a plasmid system could be clinically applied. Although there has been much improvement in the efficiency of local plasmid injection, particularly with electrotransfer, the technology is still severely limited for use in DMD as only individual muscles can be treated.
Multiple muscle groups can be transfected efficiently with plasmid DNA by optimized intravenous and intraarterial approaches An important feature of any gene therapy system is that the vector can be delivered efficiently and safely through the vascular system with the potential for readministration. Much progress has been made with the regional delivery of plasmid DNA through the vasculature to treat multiple muscle groups within a limb with a single injection. The majority of groups working in this area have concentrated on delivery of plasmid through the arterial route, with plasmid delivered in large volumes under high hydrostatic pressure. This method has achieved high levels of expression with reporter genes in large animal models such as non-human primates, although levels of expression were variable within different muscle groups of the treated limb. Danialou et al. 17 have demonstrated that this variability correlated with i.m. pressure. This delivery method relies on high pressure causing extravasation of fluid (containing plasmid) out of the microvasculature and into the muscle tissue. This results in oedema of the muscle and, therefore, increased pressure within the muscle. The anatomical location of the muscle dictates by how much the muscle can swell; for example, the tibialis anterior (TA) muscle is surrounded by both the tibia bone and a thick layer of fascia and cannot expand readily as the fluid is forced into the muscle tissue. Hence, the TA has a high i.m. pressure and a low transfection efficiency. It is considered that such high pressures result in collapse of the microvasculature such that extravasation cannot occur. By reducing hydrostatic pressure (by reducing volume injected), 22% of all fibres and a maximum of 60% of muscle fibres could be transfected in a pig's hind limb. 17 The successes achieved in the large animal models have lead to intra-arterial delivery of dystrophin plasmids in the mdx mouse. However, the results here have not been as spectacular, with Liang et al. 18 achieving an average of 30% transfection of dystrophin in the mdx hind limb, and Zhang et al. 19 a 5% transfection rate. The discrepancies between the large and small animal models may be due to technical difficulties in the mouse, and due to the larger size of the dystrophin plasmids (approximately 20 kb) compared with the reporter plasmids (7-8 kb) used in the large animal model studies. Zhang et al. 19 demonstrated that increasing plasmid size has a dramatic effect on transfection efficiency. In addition, the group of Jon Wolff 20 has developed a similar procedure to deliver plasmid intravenously. Similar levels of transfection can be achieved as with the arterial route, but with much lower injection volumes and rates. Up to 45% transfection was demonstrated in the rat following a single injection, with up to 80% transfection following three injections, indicating that not only can repeat injections be tolerated, but these also lead to a cumulative effect on transfection efficiency. The procedure has been well tolerated in the mdx mouse, rat, dog and monkey, with no evidence of toxicity or muscle damage, with the exception of transiently elevated creatine kinase levels in monkeys, which had two limbs treated at once. Importantly, no vascular damage to the veins could be detected following plasmid delivery. It is likely that the ability to use a venous administration site along with lower injection volumes and lower rates of injection may make this a more clinically relevant approach than intra-arterial injection. A phase I/II trial is currently in preparation to deliver full-length dystrophin under the control of the CMV promoter by the intravascular route to the muscles of the forearm (www.transgene.fr/us).
Novel adeno-associated viral serotypes lead to very efficient systemic transduction of skeletal muscle with truncated microdystrophin cDNAs Adeno-associated viruses (AAV) have become a very popular gene delivery system, based on their efficiency of transduction, relative inability to induce a cellular immune response in humans and their low levels of toxicity in animal studies in comparison with other viral delivery systems. AAV vectors exhibit extremely stable expression for the lifetime of a mouse and over several years in larger animal models. A severe disadvantage of AAV vectors for DMD gene therapy is their limited cloning capacity. Much research has been conducted based on extrapolation of DMD/BMD patient information and transgenic animal studies in order to engineer a microdystrophin gene, which expresses a truncated but highly functional protein (reviewed by Athanasopoulos et al. 21 and Blankinship et al.
22
). These microproteins tend to have common deletions of the central rod domain and carboxy terminus leaving vital binding domains intact Duchenne muscular dystrophy gene therapy K Foster et al ( Figure 1 ). Such proteins have been demonstrated both to improve the specific force in mdx muscle and to protect against damage caused by eccentric contractions 23, 24 following i.m. injection.
As with non-viral delivery, the ability to deliver vector systemically and safely to target all striated (including respiratory muscles) and cardiac muscle is the Holy Grail for DMD gene therapy. The last 2 years have seen enormous progress made on this front, largely owing to the isolation and development of over 100 novel AAV serotypes. 25, 26 Serotypes such as AAV1, -6, -7, -8 and -9 have been demonstrated to have high affinity for skeletal and cardiac muscle. In a similar manner to plasmid gene transfer, these novel serotypes have been successfully delivered by high pressure intra-arterial delivery to mdx mice. 27, 28 In addition, very high levels of skeletal and cardiac muscle transduction have been achieved in the rat and dog following intravenous infusion to isolated hind limbs or myocardium. 29 Su et al. 29 have also developed what is termed 'hemibody infusion' which results in high levels of expression in both hind limbs and pelvic muscles of the rat. Clearly, the ability to transfer such systems from the lab to the clinic is likely to be of paramount importance for the treatment of DMD.
However, further success has been achieved, initially by Gregorevic et al., 30 in producing body-wide expression of reporter genes and microdystrophin in the mdx mouse following a simple low-pressure intravenous injection of AAV6. With high doses of AAV6 (1 Â 10 12 / mouse), more than 90% of muscle was transfected, importantly including diaphragm and cardiac muscle. Similar levels of transduction were achieved with a lower dose of virus (2 Â 10 11 /mouse) when administered with vascular endothelial growth factor (VEGF-165). VEGF-165 was co-administered to transiently increase microvasculature permeability. However, when AAV6 microdystrophin under the control of a muscle-specific promoter was administered, a more mosaic pattern of expression was achieved, but was still able to reduce the susceptibility of dystrophic muscle to the damage caused by eccentric contractions. 30 However, injection of a higher dose (1 Â 10 13 +VEGF-165) led to body-wide expression of microdystrophin at near wild-type levels. Similar results have more recently been achieved with AAV8, expressing a reporter gene in the absence of VEGF co-administration. 31, 32 Although the development of alternative AAV serotypes has led to high levels of transduction in skeletal, respiratory and cardiac muscle, there are a number of considerations to be examined. Micro-dystrophin ∆R3, R4-R21, CT cDNA 3.9kb Methods enabling the lowering of viral dose must be further investigated, although with the development of 'custom made' serotypes to improve tropism further this approach may become feasible. 33, 34 Further, the use of regional infusion of vectors may also allow lower doses of virus to be used.
For some applications, the use of self-complementary AAV (scAAV) vectors is a possibility. AAV vectors have single-stranded DNA genomes and second strand synthesis may be considered a rate-limiting step in expression from AAV vectors. The development of AAV vectors packaged with self-complementary genomes bypasses this step and results in improved levels of expression compared with single-stranded AAV vectors. 32, 35 However, scAAV vectors have a reduced cloning capacity (max. 2.5 kb) making this technology currently unsuitable for microdystrophin delivery.
Of paramount consideration is immunity to the vector and the potential need for vector readministration. Initial immunity to the vector may be avoided by the use of serotypes not common to the human population, 26, 36 or the use of vectors based on non-human AAV. 37 Although AAV vectors are know to persist in animal models for long periods of time, it is envisaged in diseases such as DMD that vector will need to be readministered as a result of muscle turnover. It is possible that immunity to the initial vector may be overcome by the use of an alternative serotype 38 or by the development of vectors with the ability to evade antibody neutralization. 33 As with all vectors, the potential mutagenic effects must be assessed, 39 especially in light of AAV-based transgene expression being detected in Sertoli and spermatogonia cells following intra-myocardial injection of an AAV2 vector. 40 In spite of these further questions, this work represents a major step forward in DMD gene therapy. Many of these questions will be further resolved with scale up experiments in larger animal models, such as the dystrophic Golden Retriever dog, addressing issues such as viral titres required and the functional capacity of microdystrophins.
A phase I/II clinical trial for the delivery of microdystrophin by AAV has been initiated by J Mendel and X Xiao, using a microdystrophin molecule driven by the CMV promoter that has demonstrated pathophysiological improvements in mdx muscle. The AAV serotype used in this trial is AAV2.5. This serotype differs from AAV2 capsid at five amino acids. These changes increase the transduction efficiency 40-fold. This is a dose escalation study with vector being administered i.m. into the bicep muscle of 410 years DMD patients.
Expanding the packing capacity of AAV allows delivery of larger dystrophin molecules to dystrophic muscle A major limitation of AAV applications is the relatively small cloning capacity, of up to 5 kb. Recent developments in AAV technology have led to a substantial increase in the size of cDNA, which may be delivered with this technology. Firstly, the use of 'overlapping' AAV vectors, where the gene is split into two partially overlapping regions and then packaged into separate vectors, has been successful. Expression of the full-length protein is achieved following co-infection of the same cell with both vectors followed by homologous recombination of the two genomes. Up to 80% of the mouse TA muscle has been transfected with this approach using AAV6 vectors. 41 However, the efficiency of the system is dependent upon the viral serotype and the gene used. For example, injection of AAV6 overlapping vectors produced significantly higher levels of transfected fibres than injection of AAV5 containing the intact gene, and much higher levels of expression were achieved when an alkaline phosphatase gene was used compared with LacZ. The second approach is based on 'trans-splicing' vectors and is technically more demanding. 42 This again involves the splitting of gene with the incorporation of splice donor and acceptor sites at the respective ends of each clone and packaging in separate AAV vectors. Following co-infection into a cell, the inverted terminal repeat regions of the two genomes must recombine in a head-to-tail orientation. During transcription, the splice donor and acceptor sites incorporated into each clone are recognized and the two genomes are spliced together to produce an intact cDNA. This method has successfully been used with AAV6 vectors to express the 6 kb minidystrophin gene in dystrophic muscle. Eighty per cent transfection was achieved following direct injection into the TA muscle. 43 Two months post-injection muscles showed improved specific force and increased protection against eccentric contractions. Although the same considerations as described above must also be taken into account here, it is a step forward in delivering a larger dystrophin protein containing more functional domains and which has been shown to be a highly functional protein in transgenic mice.
Improved chemistries of antisense oligonucleotides improve efficiency of exon skipping
Dystrophin is unique in that drastic truncation of the protein can result in a highly functional protein. DMD is caused by frameshift mutations in the dystrophin gene resulting in no functional dystrophin being produced. However, the repetitive structure of the central rod domain means that large portions of this region can be deleted by the occurrence of in-frame mutations leading to a mild BMD-like phenotype. Modified antisense oligonucleotides (AOs) can be used to alter the splicing pattern of the dystrophin pre-mRNA. AOs mask specific motifs involved in normal splicing (either splice donor/acceptor sites or exon sequence enhancer (ESE) sites, 44, 45 ). This induces removal of specific exons, to either excise an exon containing a premature stop codon or remove exons flanking a frameshift deletion and hence producing an in-frame transcript and a truncated but functional dystrophin protein.
The most commonly used AO, which has a 2 0 -Omethyl phosphorothioate (2OMe AO) backbone, has been shown to induce persistent expression of dystrophin over a 12-week period in the mdx mouse TA muscle by forcing exclusion of exon 23 to produce an in-frame transcript. Dystrophin was expressed in a large proporDuchenne muscular dystrophy gene therapy K Foster et al tion of fibres and was partially able to improve specific force of muscles, but not protect against fatigue resistance.
46
AOs also have the ability to efficiently restore dystrophin expression in muscle cells from DMD patients. 47 It is estimated that targeting the exclusion of a single exon could restore the reading frame in B75% of DMD patients. More recently, multiple exon skipping has been achieved in patient cells. 48 This importantly increases the number of patients for which this strategy may be applicable, and it is estimated that B85% of patients in the Leiden database (www.dmd.nl) would benefit from this approach. 48 Secondly, the ability to skip single or multiple exons may give the potential to create deletions that are present in known asymptomatic BMD patients 49 (www.ppuk.org/library/conferences/ MDEXmuntoni.pdf).
The development of a transgenic mouse expressing full-length human dystrophin provides an in vivo model for AOs directed against ESEs to be tested. 50 Alternative chemistries to 2OMe AOs are also coming to the fore. These include morpholino AOs, locked nucleic acid (LNA) AOs, peptide nucleic acid (PNA) AOs and ethylene bridged nucleic acid (ENA) AOs. These modified chemistries have been developed to enhance high binding affinity for nucleic acids, increase nuclease resistance, and hence persistence in the cell for extended periods of time. In vitro LNAs have shown very efficient levels of exon skipping but have low sequence specificity, whereas morpholinos and PNAs demonstrated very low or no exon skipping in cultured cells. 51 However, chimeric RNA/ENA AOs have been shown to be more efficient than 2OMe AO, 52,53 but these compounds have yet to be tested in vivo. In stark contrast to in vitro studies, morpholinos' which have an uncharged backbone and are thought to be non-toxic, induce exon skipping in vivo at high efficiency, achieving up to 60% of normal dystrophin levels after a single injection. 54, 55 This difference in efficiencies seems mainly dependent upon the uncharged morpholinos ability to transfect cells in vitro. Recently, the addition of a DNA leash to the morpholinos has been employed to add charge to the molecule, and therefore allow extensive preclinical in vitro testing to be performed.
Alternative chemistries allow efficient systemic delivery of antisense oligonucleotides
As with all gene therapy systems for DMD, the development of a safe and effective systemic delivery system is crucial. Lu et al. 56 demonstrated that intravenous delivery of 2OMe AOs with the pluronic carrier F127 can induce dystrophin expression of up to 5% of normal levels in the gastrocnemius, intercostals and abdominal muscles, with lower levels of expression in other muscle groups. Although not efficient enough to show functional improvement, Lu et al. 56 have shown that systemic delivery of AOs in dystrophic muscle is possible, and importantly that repeat administration is well tolerated and can increase the number of dystrophin-positive fibres. However, intravenous delivery of morpholino AOs shows far greater promise. 54, 55 Weekly intravenous injections of the morpholinos into the mdx mouse resulted in 25% of fibres in most muscle groups expressing dystrophin, when recovered at the 3-week time point. Levels of expression were seen to be variable, both within and between muscles, but still resulted in an improvement in specific force of the TA muscle. Alter et al. 54 then increased the dose to weekly injections for 7 weeks; this dramatically improved the number of dystrophin-expressing fibres in all skeletal muscle groups (some 470%), including diaphragm, intercostals and abdominal muscles. For the first time, very efficient body-wide expression of dystrophin after a simple lowpressure intravenous injection of a non-viral vector was demonstrated. As with all systems, there are some disadvantages; importantly as yet dystrophin expression has not been achieved in the heart with this method. This is a crucial limitation as 30% of DMD patients die owing to cardiomyopathy. Also, nocturnal ventilation has led to an increase in life expectancy for DMD patients, and cardiomyopathic complications may subsequently increase.
Importantly, exon skipping will not be applicable to all patients, such as those who have mutations in promoter regions or essential functional domains. Readministration of AOs will also be necessary as these compounds have a limited half-life. Current animal studies suggest that this may not be problematic. An alternative approach to the non-viral approach has been the development of AAV vectors expressing small nuclear RNAs (snRNAs) containing antisense sequences. 28, 57, 58 Intra-arterial infusion of an AAV1 vector expressing U7 snRNA resulted in over 80% of fibres expressing dystrophin in most muscle groups of the infused limb, and showed significant protection against eccentric contraction-induced damage. Although the use of an AAV vector may provide a more sustained expression of antisense sequences, there is still the potential that readministration will be required. Other shortcomings of this system such as high titres required and immunological reactivity of the vectors will be similar to those discussed above for AAV microdystrophin studies. 
Development of adjuvant therapies
Muscle typically expresses two isoforms of insulin-like growth factor (IGF-1) resulting from the differential inclusion of part of exon 5. IGF-1Ea comprises of exons 1, 3, 4 and 6, whereas IGF-1Eb includes 49 or 52 bp of exon 5, in human or rodents, respectively. This inclusion leads to a frameshift such that the 3 0 ends of the respective peptides are different. These IGF-1 isoforms are post-translationally cleaved to yield the same 'mature' IGF-1 plus their respective 'extension' peptide. Extension peptide Eb is now commonly called mechano growth factor (MGF). The fact that overexpression of IGF-1 isoforms activates muscle myoblasts and results in muscle hypertrophy in vivo is indisputable (reviewed by Goldspink 60, 61 , Shavlakadze et al. 62 and Tidball
63
); however, IGF-1 has many varied roles in muscle biology/ pathology, such as effects on myofibre protein synthesis; 64, 65 thus, in part, the hypertrophy may be a result of the inhibition of muscle atrophy. [66] [67] [68] The different extension peptides appear to have differential roles. MGF seems to be important in the initial response to myoblast activation and proliferation, whereas IGF-1Ea seems to promote myotube fusion, maintains protein synthesis and increases serum IGF-1 binding proteins. [69] [70] [71] The use of IGF-1-based therapies for DMD should proceed with caution, as activation of the depleted satellite cell pool within dystrophic tissue could lead to an initial improvement followed by a worsening of pathology owing to exhaustion of the satellite cell pool. However, the cost-benefit ratio should be considered, as IGF-1 expression enhances the contribution of bone marrow-derived stem cells to skeletal muscle fourfold. 72 Finally, such strategies do not address the underlying pathology of sarcolemmal fragility. However, a coadministration strategy of AAV6-mediated transfer to mdx muscle of a functional dystrophin microgene and IGF-1Ea resulted in muscles with reduced myofibre degeneration, increased protection against contractioninduced injury and larger muscles with increased force output, 73 suggesting that co-administration approaches yield great promise.
Prospects
Given the recent advances within the field, the prospects for effective gene therapy seem to be an achievable goal. Optimization of vector cassette design, such as the removal of all bacterial sequences that may quench gene expression, will continue. 74, 75 Increased muscle targeting for all vector types will be important in avoiding ectopic expression, which may have immunological consequences. The current generation of AO chemistries lend themselves to ligand-mediated approaches and may also help in targeting the heart. AAV approaches will improve not only with the use of larger functional dystrophin molecules, but also with a reduction in viral titre needed for effective muscle transduction such that clinical concerns regarding viral toxaemia may be overcome.
With an effective dystrophin therapy, attention will undoubtedly focus upon the reduction of existing dystrophic pathology. Muscle hypertrophy is a balance between positive and negative regulatory systems. As discussed, IGF-1 isoforms can provide these positive signals; however, myostatin, a member of the transforming growth factor-b family, is a negative regulator of muscle mass. Inhibition of myostatin not only leads to increased muscle mass, 76 but also enhances muscle regeneration following injury, 77 reduces fibrosis 78 and reduces the pathophysiology of the mdx mouse. 79 Thus, it is envisaged that a combination of dystrophin and muscle augmentation therapies will become the cornerstone approach for future DMD gene therapy. Duchenne muscular dystrophy gene therapy K Foster et al
